This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/Pregabalin: Difference between revisions
Jump to navigation
Jump to search
>Isaak No edit summary |
>Isaak Adjust the total such that it is the sum of onset, comeup, peak and offset for the min and max respectively. |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 70: | Line 70: | ||
|OralROA_Collapsed=false | |OralROA_Collapsed=false | ||
|OralROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation.<br>'''This dosage and duration information has been sourced from [http://drugs.tripsit.me/pregabalin TripSit]''' | |OralROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation.<br>'''This dosage and duration information has been sourced from [http://drugs.tripsit.me/pregabalin TripSit]''' | ||
|OralROA_Bioavailability=~90%<ref> | |OralROA_Bioavailability=[[Oral min bioavailability::]] ~[[Oral max bioavailability::90]]%<ref name="Bockbrader2010">{{cite journal | vauthors=((Bockbrader, H. N.)), ((Radulovic, L. L.)), ((Posvar, E. L.)), ((Strand, J. C.)), ((Alvey, C. W.)), ((Busch, J. A.)), ((Randinitis, E. J.)), ((Corrigan, B. W.)), ((Haig, G. M.)), ((Boyd, R. A.)), ((Wesche, D. L.)) | journal=The Journal of Clinical Pharmacology | title=Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers | volume=50 | issue=8 | pages=941–950 | date= August 2010 | url=http://doi.wiley.com/10.1177/0091270009352087 | issn=00912700 | doi=10.1177/0091270009352087}}</ref> | ||
|OralROA_Threshold=[[Oral threshold dose::50]] [[Oral dose units::mg]] | |OralROA_Threshold=[[Oral threshold dose::50]] [[Oral dose units::mg]] | ||
|OralROA_Light=[[Oral min light dose:: | |OralROA_Light=[[Oral min light dose::50]] - [[Oral max light dose::225]] mg | ||
|OralROA_Common=[[Oral min common dose::225]] - [[Oral max common dose::600]] mg | |OralROA_Common=[[Oral min common dose::225]] - [[Oral max common dose::600]] mg | ||
|OralROA_Strong=[[Oral min strong dose::600]] - [[Oral max strong dose::900]] mg | |OralROA_Strong=[[Oral min strong dose::600]] - [[Oral max strong dose::900]] mg | ||
| Line 78: | Line 78: | ||
|OralROA_TimelineFile= | |OralROA_TimelineFile= | ||
|OralROA_TimelineWidth= | |OralROA_TimelineWidth= | ||
|OralROA_Duration=[[Oral min total time:: | |OralROA_Duration=[[Oral min total time::9]] - [[Oral max total time::17]] [[Oral total time units::hours]] | ||
|OralROA_Onset=[[Oral min onset time:: | |OralROA_Onset=[[Oral min onset time::30]] - [[Oral max onset time::45]] [[Oral onset time units::minutes]] | ||
|OralROA_Comeup=[[Oral min comeup time::1]] - [[Oral max comeup time::2]] [[Oral comeup time units::hours]] | |||
|OralROA_Peak=[[Oral min peak time::4]] - [[Oral max peak time::6]] [[Oral peak time units::hours]] | |OralROA_Peak=[[Oral min peak time::4]] - [[Oral max peak time::6]] [[Oral peak time units::hours]] | ||
|OralROA_Offset=[[Oral min offset time::4]] - [[Oral max offset time::8]] [[Oral offset time units::hours]] | |OralROA_Offset=[[Oral min offset time::4]] - [[Oral max offset time::8]] [[Oral offset time units::hours]] | ||
Latest revision as of 07:26, 13 October 2022
| SubstanceBox/Pregabalin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common names | Pregabalin, Lyrica, Nervalin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Substitutive name | 3-Isobutyl GABA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Systematic name | (S)-3-(Aminomethyl)-5-methylhexanoic acid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Psychoactive class | Depressant | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical class | Gabapentinoid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- ↑ Bockbrader, H. N., Radulovic, L. L., Posvar, E. L., Strand, J. C., Alvey, C. W., Busch, J. A., Randinitis, E. J., Corrigan, B. W., Haig, G. M., Boyd, R. A., Wesche, D. L. (August 2010). "Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers". The Journal of Clinical Pharmacology. 50 (8): 941–950. doi:10.1177/0091270009352087. ISSN 0091-2700.